Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), primarily used for glycemic control and weight management in diabetes and obesity, have shown potential in cancer prevention through various mechanisms. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.